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Abstract
Background: Previous research has demonstrated that digital CBT (dCBT), delivered via the Internet, is a scalable
and effective intervention for treating insomnia in otherwise healthy adults and leads to significant improvements
in primary outcomes relating to sleep. The majority of people with insomnia, however, seek help because of the
functional impact and daytime consequences of poor sleep, not because of sleep discontinuity per se. Although
some secondary analyses suggest that dCBT may have wider health benefits, no adequately powered study has
investigated these as a primary endpoint. This study specifically aims to investigate the impact of dCBT for insomnia
upon health and well-being, and will investigate sleep-related changes as mediating factors.
Methods/design: We propose a pragmatic, parallel-group, randomised controlled trial of 1000 community participants
meeting criteria for insomnia disorder. In the DIALS trial (Digital Insomnia therapy to Assist your Life as well as
your Sleep), participants will be randomised to dCBT delivered using web and/or mobile channels (in addition to
treatment as usual (TAU)) or to sleep hygiene education (SHE), comprising a website plus a downloadable booklet (in
addition to TAU). Online assessments will take place at 0 (baseline), 4 (mid-treatment), 8 (post-treatment), and 24
(follow-up) weeks. At week 25 all participants allocated to SHE will be offered dCBT, at which point the controlled
element of the trial will be complete. Naturalistic follow-up will be invited at weeks 36 and 48. Primary outcomes
are functional health and well-being at 8 weeks. Secondary outcomes are mood, fatigue, sleepiness, cognitive
function, productivity and social functioning. All main analyses will be carried out at the end of the final controlled
follow-up assessments and will be based on the intention-to-treat principle. Further analyses will determine
whether observed changes in functional health and well-being are mediated by changes in sleep. The trial is
funded by Big Health Ltd.
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Discussion: This study will be the first large-scale, specifically designed investigation of the health and well-being
benefits of CBT for insomnia, and the first examination of the association between CBT-mediated sleep
improvement and health status.
Trial registration: ISRCTN60530898.
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Background
The importance of insomnia
Insomnia disorder comprises a complaint of poor sleep,
with associated significant daytime effects, occurring at
least 3 nights per week for at least 3 months [1]. World-
wide, epidemiologic studies report the prevalence of a
chronic clinical insomnia disorder at 10 to 12 % [2–4].
Although prevalence is high, natural remission is low. In
one study, 74 % of those with insomnia continued to
have insomnia a year later and 46 % reported insomnia
persisting for over 3 years [5]. Traditionally considered
as ‘secondary’, subsumed as symptoms of other clinical
diagnoses within mental health care, the recently revised
Diagnostic and Statistical Manual of Mental Disorders,
version 5 (DSM-5) outlines the ‘need for independent
clinical attention of a sleep disorder’ (p. 1) [1]. This is
supported by research demonstrating not only that rates
of mental and physical health co-morbidity are high, but
that pre-existing chronic insomnia is an independent
risk factor for development of depression [6], cardiovas-
cular disease [7] and type 2 diabetes [8, 9]. From the
standpoint of public health and well-being, sleep appears
to be a more important matter than has been hitherto
recognised [10, 11].
The relationship between poor sleep, daytime functioning
and quality of life
Typically, insomnia is associated with increased fatigue,
impaired work productivity, reduced quality of life and
relationship satisfaction, as well as increased ill-health
[12–14]. Despite such evidence of poor functioning be-
ing attributed to poor sleep, and also being an essential
diagnostic criterion for insomnia, there has been com-
paratively little research on quality of life. This is all the
more surprising given that the perceived impact on per-
sonal functioning serves as an important driver of com-
plaint and of help-seeking behavior rather than simply
perceived sleep loss [15, 16]. In one large epidemio-
logical study, four of the five most commonly cited rea-
sons for seeking a sleep consultation with a health
professional, were daytime consequences of fatigue,
psychological distress, physical discomfort, and reduced
work productivity [16]. Clinician reports of patient consul-
tations, and cross-sectional and prospective questionnaire
studies [17, 18] further demonstrate that individuals with
insomnia complain of deficits in mood and cognitive abil-
ities (concentration, memory, attention), coupled with
elevated levels of anxiety, fatigue and physical pain/dis-
comfort. Thus, once a threshold of noticeable effect on
one’s life is reached, such individuals may feel motivated
to seek medical advice.
Cognitive behavioural therapy (CBT) for insomnia
CBT, regarded as the treatment of first choice for per-
sistent poor sleep [19–21] is a psychological treatment
designed to break the patterns of maladaptive thinking
and behaviour that serve to maintain insomnia. CBT
comprises a range of techniques including a behav-
ioural component (stimulus control, sleep restriction,
relaxation) combined with a cognitive (managing sleep-
related worries, the racing mind and intrusive thoughts)
and an educational (sleep hygiene) component. Meta-
analyses indicate that CBT has moderate to large and
durable effects on sleep quality, sleep efficiency, sleep
onset latency and wake time after sleep onset [22–24].
Moreover, approximately 60 % of those who receive
CBT respond to treatment and 39 % achieve remission
[25]. What is much less well-established is the effect
that CBT may have upon the daytime symptom and
functional health profile of people with insomnia.
Logically, effective treatment should alleviate such im-
pairments; and furthermore, based on the evidence that
impaired sleep may be causally related to reduced qual-
ity of life domains (well-being and impaired daytime
functional status), improving sleep should improve
functioning. There is some preliminary evidence from
secondary analyses that CBT may yield generalised ben-
efits [26–29], and even some primary data in small
samples that CBT for insomnia may reduce depressive
or anxiety symptoms [30, 31], but an adequately pow-
ered, definitive trial examining functional health status
and well-being is long overdue.
The current study
This study seeks to ascertain the impact of improved
sleep on three key areas of quality of life: functional
health status, patient-generated (sleep-related) quality of
life impairment and psychological well-being. Over the
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past 5 years, self-help CBT delivered via the Internet has
been introduced, not least because of the importance of
widening access to effective psychological therapy. Sev-
eral randomised controlled trials (RCTs) have evaluated
digital CBT (dCBT) applications; each of which has
found moderate to large improvements in insomnia
symptoms relative to waitlist groups [32–34]. Only one
programme, however, has been tested versus a placebo
intervention, demonstrating significant and sustained
improvements in sleep continuity; for example, sleep
diary-assessed sleep efficiency, sleep onset latency and
wake time after sleep onset, and self-reported global
sleep quality [34]. It is this dCBT intervention that will
be used in the present study. Data from the programme
show that more than 80 % of participants complete the
course within 8 weeks.
The primary hypotheses for the trial are that, com-
pared to sleep hygiene education (SHE):
1. The dCBT intervention will be associated with
improved functional health status by the end of
treatment (8 weeks)
2. The dCBT intervention will improve positive
psychological well-being by the end of treatment
(8 weeks)
3. The dCBT intervention will be associated with
reduced patient-generated sleep-related quality
of life impairment (8 weeks)
4. The effect of dCBT on outcomes (8 weeks) will
be mediated by sleep status during the treatment
phase (4 weeks)
The secondary hypotheses are that, compared to SHE:
1. The dCBT intervention will be associated with
reduced symptoms of negative mood, fatigue and
relationship/social dysfunction by the end of
treatment (8 weeks)
2. The dCBT intervention will be associated with
reduced problems with sleepiness, cognitive
impairment and productivity by the end of
treatment (8 weeks)
3. Improvements will be maintained at follow-up
(24, 36, 48 weeks)
4. The effect of dCBT on longer-term outcomes
(24, 36, 48 weeks) will be mediated by sleep status
during and upon completion of the treatment
phase (4, 8 weeks)
Methods/design
Research design
The study is a parallel-group, superiority, RCT of dCBT
(+ treatment as usual, TAU) versus SHE (+TAU). The
trial design is summarised in Fig. 1. The study will be
carried out completely online. Participants will access
the screening assessment, participant information state-
ment, informed consent form, allocation to condition
and intervention, and baseline and follow-up assess-
ments via web or mobile platforms (see also Additional
files 1 and 2). Participants will be able to print a copy of
the participant information statement and will have the
opportunity to contact the researchers via phone or
email before consenting. The study has received ethical ap-
proval from the University of Oxford Medical Sciences
Inter-Divisional Ethics Committee (ref MS-IDREC-C2-2015-
024) and is registered at ISCRTN (ISRCTN60530898).
Participants
We will recruit 1000 community participants. Our inclu-
sion criteria comprise: (1) a positive screen for probable
DSM-5 insomnia disorder, (2) a test score of ≤ 16 on the
Sleep Condition Indicator (SCI) [35], (3) being aged 18
or older (no upper age limit), (4) having reliable Internet
access at home or at work, and (5) being able to read
and understand English. We will screen for co-morbid
conditions and medication use at baseline but exclude
only those people whose health may be considered to be
unstable such as significant current symptoms of (a) an
additional sleep disorder (e.g. excessively sleepy and pos-
sible obstructive sleep apnoea), (b) psychosis or mania,
(c) serious physical health concerns necessitating surgery
or with a prognosis less than 6 months, (d) those
undergoing a psychological treatment programme for
insomnia with a health professional, and (e) habitual
night shift, evening, or rotating shift-workers. Informa-
tion covering (a) to (e) will be gathered using online
self-report questions, there will be no medical examina-
tions or access to medical records. We will not omit
participants who take medication for sleep problems, or
for any other physical or mental health problems pro-
viding they report their health to be stable. The study
will recruit through several channels. These may in-
clude online, print and broadcast media announce-
ments or advertisements and the use of contact lists
where adults who have volunteered to be involved in
research will be re-contacted (See Additional file 3).
For example, following completion of open access sleep
surveys such as the Great British Sleep Survey (GBSS:
www.greatbritishsleepsurvey.com or World Sleep Sur-
vey, WSS: www.worldsleepsurvey.com, which generate
data on tens of thousands of respondents). Potential par-
ticipants will also be alerted to the study by information
placed on the Sleepio® website (www.sleepio.com) and on
the Sleepio® App site (which generate data on hundreds of
thousands of respondents). Participants will not receive
reimbursement for their participation, but will be provided
with access to the dCBT programme free of charge,
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regardless of allocation to experimental condition. In-
formed consent will be obtained from all participants.
Randomisation and allocation concealment
This study will use simple randomisation with an allo-
cation ratio of 1:1, as recommended for large clinical
trials [36]. It will be carried out by the automated on-
line system. Hence the research team will be unable to
influence randomisation, and will have no access to fu-
ture allocations.
Blinding
This is a single-blind trial. Self-report assessments will
be completed online and hence the research team will
be blind to outcomes during the trial. Participants will
be informed of their randomisation outcome by an
automatic email, and so they will not be blind to treat-
ment allocation. The research team will have limited
contact with research participants and will be unable to
bias the allocation or influence the assessments. If
participants do contact the team and reveal the alloca-
tion, the assessments will remain blinded. Statistical
analyses will be conducted by an independent researcher
(RE; University of Manchester) who will have access to all
data.
Assessment points
Assessments will take place at weeks 0 (baseline), 4
(mid-treatment), 8 (post-treatment), and 24 (follow-up).
In consideration of ethical matters, at week 25 all partic-
ipants in the control group will be offered dCBT to help
with their sleep problems, and so at that point the con-
trolled element of the trial will be complete. Thereafter,
there will be a naturalistic follow-up. All participants will
be invited to complete further assessments at weeks 36
and 48.
Planned intervention
Digital cognitive behavioural therapy will be delivered
using the Sleepio® programme [34] (www.sleepio.com
Fig. 1 Summary of the trial design for the Digital Insomnia therapy to Assist your Life as well as your Sleep (DIALS) study. SCI Sleep Condition
Indicator, dCBT digital cognitive behavioural therapy, SHE sleep hygiene education
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and associated Sleepio® App). The programme is fully
automated and its underlying algorithms feed the deliv-
ery of information, support, and advice in a personally
tailored manner. Delivery is structured into six sessions,
lasting an average of 20 minutes each. Certain tools
(such as sleep diaries and relaxation audios) can also be
accessed using the web browser of any smartphone. All
of the six core sessions, sleep diaries, relaxation audios,
and the scheduling tool can also be accessed using an
iOS App, but this is only an option for participants who
have an iPhone®. The treatment content is based on
CBT for insomnia manuals [26–28] and includes a
behavioural component (sleep restriction, stimulus con-
trol, and relaxation), a cognitive component (paradoxical
intention, cognitive restructuring, mindfulness, positive
imagery, and putting the day to rest) and an educational
component (psycho-education and sleep hygiene).
The programme is highly interactive, and content is
presented by an animated virtual therapist. Participants
make a time for the session and are prompted via email
and/or short text message (SMS) if they do not ‘attend’.
Participants complete daily sleep diary information
throughout the intervention, which is used by the
programme to provide tailored, personalised help. Par-
ticipants receive an email and/or SMS reminder each
morning to prompt them to fill in their sleep diary. In
addition, participants complete a short questionnaire at
the beginning of therapy to set treatment goals. Through-
out the course of therapy, participants have access to a
moderated online community and an online library of in-
formation about sleep. Participants can view their online
case file, which includes four sections: a progress review, a
reminder of strategies to try out between sessions, an
agreed sleep schedule, and a list of further reading. The
system provides online analytics, which can be used to
monitor adherence by assessing how many sessions were
completed and the number of weeks to complete the
course. All information gathered for the programme will
be stored in encrypted form on secure servers. Passwords
are stored in encrypted form and all sensitive traffic is
transmitted securely via SSL by default. Participants will
have access to the intervention for up to 12 weeks. Digital
CBT will in effect be dCBT + TAU because there will be
no requirement for participants to alter their usual care in
any way. Physicians, for example, will be free to offer ap-
pointments, to prescribe, and to maintain/discontinue
prescriptions as they see fit.
Sleep hygiene education (SHE) has been selected for
the control arm because this is what people with insom-
nia are offered most typically in routine care. To ensure
consistency of approach and content, SHE will be deliv-
ered on a dedicated website where materials can be
viewed and downloaded. SHE will be based on recog-
nised sleep hygiene advice [37–39] and will comprise
behavioural advice concerning both lifestyle factors and
environmental factors associated with sleep and sleep-
lessness. The latter in particular will focus on creating
the optimal bedroom environment for good sleep. The
content of SHE will cover the importance of limiting
caffeine, nicotine, and alcohol and of carefully man-
aging diet and exercise (lifestyle), as well as limiting
noise and light, managing room temperature and body
temperature, and improving air quality and bed comfort
(environment). SHE will in effect be SHE + TAU be-
cause again there will be no requirement for the usual
care of participants to be altered in any way.
Outcome measures
Participants will be prompted by email to complete the as-
sessments in an online, secure environment (www.survey-
gizmo.eu). The order of the assessments will be consistent
across all participants and all time-points. If participants
do not complete measures within 2 days they will receive
further email reminders. The full battery of questionnaires
amounts to around 100 items in total, and takes 20–25
minutes to complete. We have evidence from a recently
completed protocol that data on such measures can be
successfully collected online [40]. Demographic and de-
scriptive clinical data will be gathered at baseline only.
Measurements to permit health economic evaluation will
form part of the descriptive demographic data, with some
aspects audited at each assessment point (e.g. medication
use, visits to health professionals, other health care utilisa-
tion). Descriptive data on health behaviours such as smok-
ing and alcohol use will also be reported.
The co-primary measures that relate to functional
health and well-being will be the Patient Reported Out-
come Measurement Information System: Global Health
scale [41] (PROMIS-10), the Warwick-Edinburgh Mental
Well-being Scale [42] (WEMWBS) and the Glasgow
Sleep Impact Index [43] (GSII). The PROMIS-10 is a re-
liable (α ≥ .92) but brief (10 items), generic measure that
has proven to be very useful in measuring outcomes in
clinical trials (http://www.nihpromis.org/science/). It can
also be used to estimate cost-utility using QALYs (qual-
ity-adjusted life-years) [44, 45]. The WEMWBS is a
short (14 items) and psychometrically robust measure (α
≥. 91) of mental well-being and is included because it fo-
cuses entirely on positive aspects of functional mental
health. A previous pilot trial suggests the WEMWBS is
sensitive to changes after CBT for insomnia [46]. The
GSII is a patient-reported outcome (PRO) measure that
asks patients to individually generate, and then assess,
three domains of sleep-related impairment unique to
their own individual context. Its strength is ecological
validity and the GSII has been shown to be sensitive to
change following CBT [43]. This combination of PRO,
generic functional health status, and positive mental
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state (rather than symptom reduction) matches our
intention to evaluate the impact of dCBT upon quality
of life domains.
Secondary outcomes relate to specific measurement
of the six areas of daytime consequence that are asso-
ciated with the clinical diagnosis of insomnia disorder
[1, 14, 47]. These are mood (Patient Health Question-
naire (PHQ-9: 9 items [48]) and Generalised Anxiety
Disorder (GAD-7: 7 items [49])); energy (Flinders Fa-
tigue Scale (FFS: 7 items [50]); relationship satisfaction
(Relationship Assessment Scale (RAS: 7 items [51]);
cognitive functioning (Cognitive Failures Question-
naire (CFS: 25 items [52])]; work performance and sat-
isfaction (Work Productivity and Activity Impairment
questionnaire: Specific Health Problem (WPAI:SHP: 6
items [53]), 1 item on job satisfaction [54]); and sleepiness
(Epworth Sleepiness Scale (ESS: 8 items [55]). As an ex-
ploratory measure, participants will also complete 1 item
about their general life satisfaction [56].
In order to appraise the mediating effects of sleep im-
provement per se we will use the SCI [35] and esti-
mates of sleep diary parameters [57]. The SCI is an
internally consistent (α = .86) measure with a clinical
cut off that can correctly identify 89 % of those with
probable DSM-5 insomnia disorder. The SCI and sleep
diary variables have proven to be sensitive to change
following dCBT [34].
In addition to these formal assessments the web/mo-
bile platform will provide online analytics for the dCBT
group. These can be used, for example, to measure the
process of change (sleep diary) and to monitor how
many sessions were completed and the number of weeks
to complete the course. These will be used in explora-
tory analyses. We will also gather information on the
demographics of the sample, employment, work satisfac-
tion and economic outcomes, their health characteris-
tics, and their use of clinical services during the period
of their trial participation.
Assessment of safety
The likelihood of serious adverse events occurring dur-
ing this trial is low since dCBT for insomnia has not
been reported to cause them. The intervention offered
in the trial has previously been tested in a RCT testing
change in insomnia and no adverse outcomes were re-
ported [29, 34]. However, studies have shown that day-
time sleepiness and vigilance impairment may increase
during sleep restriction therapy (SRT) (one component
of CBT-I), owing to restricted sleep opportunity [58].
We will record the occurrence of any serious adverse
events in trial participants, defined as: (1) all deaths, (2)
suicide attempts, (3) serious violent incidents, (4) admis-
sions to secure units, and (5) formal complaints about
the online intervention. Owing to the online nature of
the assessments and intervention, it is unlikely that the
research team will become aware of all such events. At
the end of treatment we will also ask participants to
complete an adapted version of a previously employed
adverse effects measure [59] to assess differential rates
of self-reported adverse effects.
Sample size calculation
Our planned primary intention-to-treat analyses will
compare dCBT + TAU versus SHE + TAU for each of the
three primary outcomes separately. Assuming a signifi-
cance level of 1.667 % (adjusted from 5 % because of
having three primary outcomes) and a power of 90 %, to
detect a standardised effect size of 0.25 we require a
minimum of 433 participants in each of the groups in
the analysis. Accounting for a conservative dropout rate
of 13 %, we will recruit 500 participants in each treat-
ment group, or 1000 participants in all. This sample size
will have more than 80 % power to detect a large-sized
indirect effect through the sleep mediator (proportion
mediated approximately 75 %) for each between-group
comparison. We believe that a sample of this size is
feasible to recruit for two reasons. First, online/mobile
interventions are much more accessible than in person
interventions; and second, published research using
dCBT has already shown that large samples may be re-
cruited over comparatively short recruitment periods.
Statistical analysis
All analyses will be carried out using Stata [60]. In ac-
cordance with Consolidated Standards of Reporting Tri-
als (CONSORT) guidelines, we will report all participant
flow. Descriptive statistics of recruitment, dropout and
completeness of interventions will be provided.
The main efficacy analysis will be via intention-to-
treat including all participants, with no planned interim
analysis for efficacy or futility. Baseline characteristics
will be presented by randomised group without formal
statistical tests. We will test the primary hypothesis for
between-group change in the primary outcomes at
8 weeks using analysis of covariance with baseline out-
come measure and treatment assignment as fixed effects,
and apply standard regression diagnostics. The analysis
will use statistical techniques for handling missing out-
come data under a missing-at-random assumption. The
secondary outcomes will be analysed using an analogous
method, as will subsequent measures of the primary out-
comes at 24 weeks. Analysis of all treatment effects will
be undertaken after all 24-week outcome measures are
completed.
We will use modern causal inference methods to in-
vestigate the mediation hypothesis [61]. If the efficacy
analysis shows significant between-group differences in
the SCI at 4 and 8 weeks, then we will use parametric
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regression models to test for the indirect effect of SCI
on outcomes, and the residual direct effect of treatment
on outcomes at 8 and 24 weeks respectively. Since all
the measures are continuous, the indirect effects are
calculated by multiplying relevant pathways and boot-
strapping is used to produce valid standard errors for
the indirect effects. All analyses will adjust for baseline
measures of the SCI, outcomes and putative measured
confounders. Mediation analyses are potentially biased
by measurement error in mediators and hidden con-
founding between mediators and outcomes and we will
investigate the sensitivity of the estimates to these
problems.
Dissemination policy
Results from this study will be published in peer-reviewed
scientific papers, and presented at major national and
international clinical scientific meetings. Findings, wher-
ever possible, will be made accessible online, dependent
upon journal policies.
Discussion
It is already well-established that CBT is the treatment
of first choice for people with chronic insomnia, and
that sleep-related outcomes, whether on index mea-
sures of insomnia or on derivations from sleep diaries,
show sustained improvement [19–21]. A recent defini-
tive placebo-controlled RCT has also demonstrated that
dCBT yields effect sizes that mirror conventionally de-
livered face-to-face therapy [34]. What is yet to be
established is whether or not CBT for insomnia is caus-
ally associated with changes in functional health, qual-
ity of life and psychological well-being. This is crucial
for two reasons. First, a diagnosis of insomnia disorder
cannot be made unless there are clear attributed day-
time consequences of night-time poor sleep; and sec-
ond, it is the degradation of people’s lived experience
and quality of life that often leads to clinical complaint
and help-seeking behaviour. An investigation of such as
primary outcomes is long overdue. This study will be
the first specifically designed investigation of the health
and well-being benefits of CBT for insomnia, and the
first large-scale test of the relationship between CBT-
mediated sleep improvement and health status. The re-
sults can be expected to influence care provision for
the 10–12 % of the adult population who have persist-
ent insomnia problems. In particular, the results may
indicate that sleep is a novel therapeutic target in rela-
tion to generalised health benefit and improved quality
of life. Moreover, because we will be using a dCBT
approach, a scalable solution to insomnia may be dem-
onstrated as both viable and effective.
Trial status
Recruitment will begin in December 2015. It is anticipated
that recruitment will be complete in Summer 2016.
Therefore, trial results will become available in late 2016.
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